New pill targets rare cancer drivers in chinese patients

NCT ID NCT04280081

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and doctors monitor their response using standard cancer measurement criteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selpercatinib (a targeted oral drug that blocks RET proteins driving cancer growth)
What this could lead to: If successful, this could provide a new treatment option for people in China with certain RET-altered cancers, potentially shrinking tumors and delaying progression.
What could go wrong: This is a mid-stage trial with only 77 participants, so results may not apply broadly. Selpercatinib can cause side effects like liver issues, high blood pressure, and fatigue, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDULLARY THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary medullary thyroid gland carcinoma neoplasm non-small cell lung carcinoma RET fusion positive cancer Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEDULLARY THYROID CANCER SOLID TUMOR

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China
Hunan Cancer Hospital

Changsha, Hunan, 410013, China
Jilin Cancer Hospital

Changchun, Jilin, 130000, China
Jinan Central Hospital

Jinan, Shandong, 250013, China
Shanghai Chest Hospital

Shanghai, Shanghai/China, 200030, China
Shanghai East Hospital

Shanghai, Shanghai Municipality, 200120, China
Southern Medical University Nanfang Hospital

Guangzhou, Guangdong, 510515, China
The First Affiated Hospital Of Guangzhou Medical University

Guangzhou, Guangdong, 510120, China
The First Affiliated Hospital, Zhejiang University

Hangzhou, Zhejiang, 310003, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, 300060, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China
Zhejiang Provincial People's Hospital

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.